PolyPid Ltd. POLY 深 沪
已收盘 08-29 16:00:00 美东时间
39.82
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 39.82
- 总市值 175.18万
- 52周最高 40.82
- 市盈率 静 97.67
- 换手率 0.00%
- 52周最低 22.69
- 委 比 0.00%
- 总股本 4.40万
- 历史最高 81.23
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.60
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
PolyPid Ltd. (Nasdaq: PYPD) announced it will report its Q2 2026 financial results and operational highlights before the U.S. market open on August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide a business update. Registration is recommended 5 minutes prior to the call. For more information, visit PolyPid's website or contact investor relations.
07-30 12:00
PolyPid rises as lead product granted FDA priority review
PolyPid (PYPD) added more than 7% on Wednesday after the Israeli biopharma received the FDA's priority review for a marketing application seeking U.S. approval for its lead product candidate D-PLEX100...
07-30 02:20
PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront Payment
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has entered into an exclusive commercial partnership agreement (the "Agreement") with Azurity Pharmaceutic...
07-21 19:32
PolyPid Completes Its New Drug Application Submission On Rolling Review Basis Top FDA For D-PLEX100 To Prevent Surgical Site Infections
PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced the
06-01 20:40
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
PolyPid Ltd. (Nasdaq: PYPD) announced it will report its first quarter 2026 financial results and operational highlights on Wednesday, May 13, 2026, before the U.S. market open. A conference call and webcast at 8:30 AM Eastern Time will discuss the results and business updates. The company, focused on improving patient outcomes through innovative biopharmaceuticals, invites participants to register in advance for the call or listen via webcast.
05-06 12:00
PolyPid To Present ASEPSIS Analysis Data From Its Phase 3 SHIELD II Study Of D-PLEX At 5th Annual Meeting Of The Surgical Infection Society
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that
04-28 20:37
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that
04-13 21:16
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
PolyPid Ltd. has initiated the submission of its New Drug Application (NDA) to the FDA for D-PLEX₁₀₀, aimed at preventing surgical site infections (SSIs) in colorectal surgery patients. The submission, under the FDA’s Fast Track designation, includes the Chemistry, Manufacturing and Controls (CMC) and nonclinical sections, with the clinical section expected in the second quarter of 2026. D-PLEX₁₀₀, which uses PolyPid’s Kynatrix technology, provid...
03-31 12:30
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
PolyPid Ltd. announced that the FDA has granted a $4.3 million small business waiver for its New Drug Application (NDA) for D-PLEX₁₀₀, aimed at preventing surgical site infections in abdominal colorectal surgeries. This waiver supports the company's commercialization efforts and enables it to focus on submitting the first sections of its rolling NDA by the end of this month. D-PLEX₁₀₀ demonstrated a 60% relative risk reduction in infections in th...
03-17 12:30
PolyPid Appoints Brooke Story As Board Chairman, Effective Dec. 11
PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors,
2025-12-16 21:33
